NPPG Administrator, Suite 213, Boundary House, London W7 2QE
Recent consultations NPPG has responded to as of December 2025
Thank you to our committee members and our specialist interest groups for the comments received on recent consultations.
Since the previous full committee meeting the following consultations have been reviewed:
Consultations
Thank you to our committee members and our specialist interest groups for the comments received on recent consultations and to those who have volunteered to be nominated experts.
The following consultations have been reviewed since the last full committee meeting.
| NICE STA | Depemokimab for treating severe eosinophilic asthma in people 12 years and over, ID 6447 | 16/06/25 | Deadline for comments; 12/08/2025 | Circulated to committee members 17/06/25. Comments received were submitted 07/07/25 | Comments from Sukeshi and forms submitted 09/07/25 |
| NICE STA | Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | 02/07/25 | Expert nomination – 04/09/2025 Organisation submission – 04/09/2025 |
Circulated to committee members 04/07/25. | No comments received. A ‘No comment’ response submitted 04/09/2025 |
| NICE STA Draft Scope Consultation |
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448 | 08/07/25 | Deadline for comments – 05/08/2025 | Circulated to committee members 09/07/25 | No comments received. A ‘No comment’ response submitted. 05/08/2025 |
| NICE STA | Resmetirom for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatotic liver disease [ID6529] | 10/07/2025 | Expert nomination – 12/09/2025 Organisation submission – 12/09/2025 |
Circulated to committee members 11/07/25 | |
| NICE STA Draft Scope Consultation |
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557 | 11/07/25 | Deadline for comments – 08/08/2025 | Circulated to committee members 11/07/25 | No comments received. A ‘No comment’ response submitted. 08/08/2025 |
| NHSE Genomic Medicine Service | https://dmscdn.vuelio.co.uk/publicitem/5377f31b-d39b-4c51-a116-48e49d9be036 | 29/07/25 | Deadline 12pm on Friday 22nd August. | Circulated to committee members 29/07/25 | Comments from Nigel Gooding received 04.08.2025. Comments from Nicola Hussein added to Nigel’s comments. Comments submitted. |
| NICE STA Draft Scope Consultation |
Spinal muscular atrophy – onasemnogene abeparvovec (intrathecal) ID6556 | 04/08/25 | Deadline for comments – 02/09/2025 | Circulated to committee members 05/08/2025 | No comments received. A ‘No comment’ response submitted. 02/09/2025 |
| NICE STA Draft Scope Consultation |
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537 | 27/08/25 | Deadline for comments – 24/09/2025 | Circulated to committee members 01/09/2025 | |
| NICE STA Draft Scope Consultation |
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510 | 27/08/25 | Deadline for comments – 24/09/2025 | Circulated to committee members 01/09/2025 | |
| NICE STA Invitation to participate |
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457] | 28/08/25 | Expert nomination – 30/10/2025 Organisation submission – 30/10/2025 |
Circulated to committee members 01/09/2025 | |
| NICE STA Draft Scope Consultation |
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446 | 03/09/25 | Deadline for comments – 01/10/2025 | Circulated to committee members 03/09/2025 | |
| NICE STA Draft Scope Consultation |
Orforglipron for managing overweight and obesity ID6516 | 04/09/25 | Deadline for comments – 02/10/2025 | Circulated to committee members 04/09/2025 |
CCA – Cost Comparison Appraisal; STA – Single Technology Appraisal; QSU – Quality Standard Update; SpecComm – Specialised Commissioning; MTA – Multiple Technology Appraisal; HTSE – Highly Specialised Technologies Evaluation.
Information Officer Work plan as at 2nd December 2025
Note: limited service from RDTC at present due to long-term sickness
| Item | Comments | Progress |
| Vitamins comparison document to support position statement | Many emails sent and received, and versions drafted, checked and shared with AW, CP, NV and within RDTC. | Added Paravit-Mod and to add HealthyStart and updated July 2025. |
| Medicines Shortages Work | CP attends the Department of Health and Social Care (DHSC) fortnightly meetings to provide Paediatric Expert input. | |
| Spironolactone 50mg/5ml licensed oral solution FAT | Additional product came to market so evaluating tow products one of which seems to have a better excipient profile for paeds than the other. | Published. |
| Vancomycin oral solution FAT | Identified as useful, but not an immediate priority. To be added to RDTC publications work plan and started early July 2025. | This was started and every effort made to obtain information from the manufacturer and hospital departments using it but consider that there is not enough info to progress to publication. |
| Monthly Horizon Scanning | RDTC produce monthly horizon scanning reports. Information Officer Team to review them to identify any products likely to have an impact on paediatric prescribing or practice. | Monthly – looking to identify potential products with paediatric relevance. |
| Survey of members about issuing Dry Powder Antibiotics | This was proposed by Chris as something he was considering looking at, to understand what other paediatrics departments do. NC agreed to Survey Monkey approach. | Presented at conference November 2025. Plan to develop patient information leaflet (in contact with Medicines for Children) and/or best practice guide. |
| RCUK Paediatric Quick Reference Handbook review | Chris Paget is reviewing on behalf of NPPG | Completed. |
| Excipient Position Statement – evidence review | RDTC is worked through the evidence for this document. | Andy Wignell sent back comments November 2025 – needs review. |
| Propylene Glycol and dexamethasone | RDTC will look at this as part of the excipient evidence review work | Evidence review completed and disseminated to neonatal SIG. |
| Review of UKCPA perioperative handbook monographs | Plan to scope out 10-20 commonly used medicines to assess feasibility and need for review, | Expressions of interest received from NPPG members to set up project group.
Meeting with UKCPA w/c 08/12/2025 |
| Measles and vitamin A | Evidence search for dosing and available preparations | On hold due to sickness |
| What is the evidence for alternatives to triamcinolone for paediatric indications: JIA, keloid scarring, asthma, allergies? | In advance of Triamcinolone supply being discontinued. | Started but delayed due to annual leave and sickness. |
| Psychological effects of medicines literature search | Clarity on the remit was received from S Tomplin:
“The question that was raised was – do we have proof that psychological change from medicines is of real concern to parents / carers? 1. The effects of medicine psychological change in children – on the child / on the carer? 2. Attitudes of parents towards psychological change in children due to medicines? “ |
Started but delayed due to annual leave and sickness. |
| Article for Archives Education and Practice | Approached to have article about being commissioned to write an article about supporting paediatric formulary decisions and what to consider | To rediscuss when team back from sick leave. |
| Message board enquiries | Responding ad hoc to queries directly or redirecting to specialists / specialist groups in case they may be able to help.
Posting article notifications considered of interest to members. |
Ongoing. Look at notice board at least weekly for suitable enquiries for Information Officer Response. |
Elizabeth Okpara is now supporting NPPG work along with Paula Russell. RDTC also have identified admin support for the circulation of NICE consultations. Weekly Northern Consortium Team meetings are continuing.
CCA – Cost Comparison Appraisal; STA – Single Technology Appraisal; QSU – Quality Standard Update; SpecComm – Specialised Commissioning; MTA – Multiple Technology Appraisal; HTSE – Highly Specialised Technologies Evaluation.